MRK Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 32.71% compared to Merck &'s net margin of 19.72%. Merck &'s return on equity of 39.02% beat Gilead Sciences's return on equity of 32.29%.

Merck & has a consensus price target of $101.79, signalling upside risk potential of 23.48%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 6.37%. Given that Merck & has higher upside potential than Gilead Sciences, analysts believe Merck & is more attractive than Gilead Sciences.

Merck & has a beta of 0.389, which suggesting that the stock is 61.063% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.88%. Gilead Sciences offers a yield of 2.84% to investors and pays a quarterly dividend of $0.79 per share. Merck & pays 45.8% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Merck & quarterly revenues are $15.5B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Merck &'s net income of $5.1B is higher than Gilead Sciences's net income of $1.3B. Notably, Merck &'s price-to-earnings ratio is 12.00x while Gilead Sciences's PE ratio is 23.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.27x versus 4.82x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 32.71% compared to Merck &'s net margin of 23.32%. Merck &'s return on equity of 39.02% beat Johnson & Johnson's return on equity of 30.18%.

Merck & has a consensus price target of $101.79, signalling upside risk potential of 23.48%. On the other hand Johnson & Johnson has an analysts' consensus of $170.92 which suggests that it could grow by 3.36%. Given that Merck & has higher upside potential than Johnson & Johnson, analysts believe Merck & is more attractive than Johnson & Johnson.

Merck & has a beta of 0.389, which suggesting that the stock is 61.063% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.88%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.30 per share. Merck & pays 45.8% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.5B, which are smaller than Johnson & Johnson quarterly revenues of $23.7B. Merck &'s net income of $5.1B is lower than Johnson & Johnson's net income of $5.5B. Notably, Merck &'s price-to-earnings ratio is 12.00x while Johnson & Johnson's PE ratio is 17.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.27x versus 4.41x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 32.71% compared to Merck &'s net margin of -907.48%. Merck &'s return on equity of 39.02% beat Moderna's return on equity of -29.23%.

Merck & has a consensus price target of $101.79, signalling upside risk potential of 23.48%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Moderna has higher upside potential than Merck &, analysts believe Moderna is more attractive than Merck &.

Merck & has a beta of 0.389, which suggesting that the stock is 61.063% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.88%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & pays 45.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.5B, which are larger than Moderna quarterly revenues of $107M. Merck &'s net income of $5.1B is higher than Moderna's net income of -$971M. Notably, Merck &'s price-to-earnings ratio is 12.00x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.27x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 32.71% compared to Merck &'s net margin of 23.33%. Merck &'s return on equity of 39.02% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Merck & has a consensus price target of $101.79, signalling upside risk potential of 23.48%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 6.55%. Given that Merck & has higher upside potential than Vertex Pharmaceuticals, analysts believe Merck & is more attractive than Vertex Pharmaceuticals.

Merck & has a beta of 0.389, which suggesting that the stock is 61.063% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.044%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.88%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & pays 45.8% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.5B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.8B. Merck &'s net income of $5.1B is higher than Vertex Pharmaceuticals's net income of $646.3M. Notably, Merck &'s price-to-earnings ratio is 12.00x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.27x versus 10.96x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.